MED12 and leiomyosarcoma: These studies suggested that the MED12 exon 2 mutations may be unique to uterine leiomyomas and a subgroup of leiomyosarcomas; however, interestingly, a recent study using exome analysis of fibroadenomas revealed highly frequent MED12 exon 2 mutations (58/98, 59%).